Brief: Novartis Igan Data Slowed Kidney Function Decline By 49.3%

Novartis AG

30/03/2026 06:11

March 30 (Reuters) - Novartis AG NOVN.S said on Sunday:

Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study

40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years

Fabhalta granted priority review by FDA for traditional approval

 Further company coverage: [NOVN.S]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))